Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01621399 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy Study to Treat Bacterial Vaginosis

A Phase 3 study, sponsored by Medicis Global Service Corporation.

Completed
Registry status
Phase 3
Development phase
651
Enrollment target

NCT01621399: Completed Phase 3 study, sponsored by Medicis Global Service Corporation.

NCT01621399 is a Phase 3 study that has completed, run by Medicis Global Service Corporation. The registered enrollment target is 651 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01621399, a Phase 3 study, has completed, sponsored by Medicis Global Service Corporation.

COMPLETED
Registry status
Phase 3
Development phase
651 participants
Enrollment target

Study Summary

The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.

Primary Outcome

The proportion of subjects with a clinical cure at the Day 21 visit, as assessed by the investigator.

Interventions

  • DRUG Product 55394
  • DRUG Placebo Vehicle (non-treatment)

Trial Details

FieldValue
Enrollment Target 651 participants
Start Date 2012-05
Est. Completion 2012-12
Phase Phase 3
Medicis Global Service Corporation

10 total trials

What the finished NCT01621399 record still lists

NCT01621399 is an interventional study that assigns participants to a tested intervention. The registered 651 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (16% lower).

The record links to 0 conditions, and to 2 interventions - of which Product 55394 is the first listed.

NCT01621399 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01621399 about?

NCT01621399 is a clinical study titled "Safety and Efficacy Study to Treat Bacterial Vaginosis". The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.

What is the current status of trial NCT01621399?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 651 participants. The study started on 2012-05. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01621399?

The interventions under investigation include: Product 55394 (DRUG), Placebo Vehicle (non-treatment) (DRUG).

Who is sponsoring clinical trial NCT01621399?

This trial is sponsored by Medicis Global Service Corporation, which has 10 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01621399's enrollment target sits among peer trials

651 572nd of 2000 higher than 1,429 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06287346 · 652 participants

    5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.

  • NCT02934477 · 650 participants

    Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

  • NCT04579120 · 650 participants

    Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

  • NCT04875702 · 650 participants · Phase 4

    Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01621399, the US trial registry maintained by the National Library of Medicine. NCT01621399 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.